Related Parties

9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Related Parties

11. Related Parties

On October 24, 2017, the Company announced a strategic research collaboration with Mosaic Biosciences, Inc. (“Mosaic”) to develop intravitreal anti-complement factor 3 products for the treatment of dry age-related macular degeneration and other retinal diseases. According to the agreement the Company and Mosaic will co-fund the research. Dr. Usman, the Company’s Chief Executive Officer and a member of the Company’s board of directors, and Mr. Lawlor, the chairman of the Company’s board of directors, were also members of the board of directors of Mosaic when this agreement was entered in to, and the agreement was reviewed by disinterested members of the Company’s board of directors and approved by the Company’s audit committee. Expenses related to the collaboration were $0.3 and $0.5 million for the three months ended September 30, 2019 and 2018, respectively. Expenses related to the collaboration were $0.8 and $0.9 million for the nine months ended September 30, 2019 and 2018, respectively.